Sponsored by the HealthcareTrainingInstitute.org providing Quality Education since 1979
Add to Shopping Cart

HIV: Therapeutic Strategies for Guilt. Uncertainty, and Taking Control Abbreviated, Part II
HIV: Therapeutic Strategies for Guilt. Uncertainty, and Taking Control Abbreviated, Part II

Section 9
Treating HIV Positive Adolescents, Part 1

Question 9 | Answer Booklet | Table of Contents | HIV/AIDS CEU Courses
Social Worker CEUs, Psychologist CEs, Counselor CEUs, MFT CEUs

The primary focus of this study was to explore the most difficult aspects of being infected with HIV for the adolescent. As mentioned previously, adults with HIV have been found to experience psychological as well as social ramifications from their diagnosis. Many of these themes became clearly evident while interviewing adolescents living with HIV. Four specific themes, or categories, of difficulties emerged: disclosure, medical adherence, relationships, and psychological burden.

Disclosure
Responses in this category encompassed difficulties that participants had experienced in disclosing their HIV status to other people. Five participants (2 males, 3 females), 63% of the sample, gave responses that referenced disclosure. Two themes that became obvious, yet are distinctly intertwined, are fear of the actual disclosure as well as fear of the ramifications that follow a disclosure to someone.

How do I tell them? For the participants, this theme focused on the actual event of disclosing their HIV status to someone. For example, participants feared how they would tell someone, what words they would use, and how they would react to different facial responses by the person to whom they were disclosing. For the most part, the participants feared having to tell someone close to them that they have a highly stigmatized and life-threatening disease. One said, "I'm just torn apart right now because I don't tell my parents yet about my status, and I know it's going to be hard for my mom, so I don't know how to tell her about this thing." Another participant commented, "But I don't know ... how you talk to somebody and they don't know you're positive and you tell them that you're positive, you can just, you can see the change. And it's like it never goes away."

What will they do or say? The second theme that stems from difficulties with disclosure is the ramifications or consequences of telling someone. Many of the participants feared hurting the people to whom they were disclosing. Some participants also feared being hurt by the behavioral or emotional response of the person to whom they disclosed. Several of the participants were also afraid of social and emotional isolation as a result of disclosure. "Maybe they, when they know my situation, they maybe say `I told you so,' " said one participant. Another commented, "People may look at you as someone nice, and once they find out you're positive ... they just hate you."

Medical Adherence
Responses within this category expressed participants' experiences with the numerous types of medication that they take for HIV as well as the difficult medication schedules that they must follow. Seven participants (3 males, 4 females), 88% of the sample, made reference to the difficulties involved in medical adherence. These responses can be broken down more succinctly into two subcategories: what the medications mean to the participant, and practical difficulties with taking the medicines.

Meaning of the medication. The following group of responses indicate that, for these participants, the HIV medication often takes on an underlying meaning to them. These underlying meanings can be further broken down into two different themes. In the first theme, the participants appear to view the medication as a lifeline, a necessary evil that keeps them alive.

"It's just a necessary evil basically, taking the medicines and stuff like that. It's something that I'm not happy I have to deal with but it's just, I do what I do to stay healthy and alive, basically," said one. Another observed, "I don't think of my medicine [negatively], I think it is better for me, like vitamins three times a day."

In the second theme, the medication serves only as a reminder of the disease. In this theme the medicine precipitates negative psychological reactions and forces the participants to be confronted with the fact that they are infected with HIV. On participant said, "For the longest time I didn't [believe I had HIV] until I had to start taking medication. And then it was like it all hit the fan because I had it for almost a year and a half but I really, you know, don't mean that I had it until I had to start taking medication, and man, I just broke down and it was horrible." And another commented, "I just made 20 in February. I was thinking, man, I'm only 20 and now I've gotta take medication to keep me alive, and I just freaked out. Oh, just freaked out."

Difficulties with medications. Responses in this subcategory reflect the different types of difficulties the participants have experienced with their medication regimes. Within these responses, several themes appear. Responses in the first theme category indicate that HIV medication can cause difficulties related to disclosure. If people see the participant taking the medication, it may cause questions to be asked that the participant would rather avoid. "For me, when I drink my medicine at my work, you know, maybe the people ask, `When you take medicine, why you take medicine? What is this?' And I can't explain to everybody my situation."

The second theme represents the physical discomfort associated with many of the medications for HIV. This discomfort creates difficulties in social and behavioral functioning that tend to further the participants' dislike for the medication. This dislike can exacerbate issues of non-adherence.

"It's not a fun thing. It's not an easy thing ... you get nauseous, some people lose weight because they just have no appetite, some of these pills I can't eat with, two hours before or after. I got to take these pills three times a day, which don't seem like a lot, but that's six hours out of the day that I cannot eat. And then my other pills I gotta eat with, so then I can't take them together ... I do it, but it ain't easy. I do it for my kids. But you shouldn't have to worry about that at my age."

Another participant confessed, "I just stopped taking it. Some of that shit made me feel horrible, and I, plus, I don't have time for it anyway because I got too much garbage on my mind to be thinking about what time to take a pill."
Finally, the third theme represents the strenuous and complicated nature of the medical regime, as well as the time commitment that is necessary for strict and successful adherence. "I have to get up in the morning, when I don't have school or anywhere to go, to take medication. Wake up to the medication time, because I need to take medication between 11:00pm and 12:00am, so I've got to wake up."
- Hosek, Sybil, Gary Harper, and Rocco Domanico; Psychological and Social Difficulties of Adolescents Living With HIV: A Qualitative Analysis; Journal of Sex Education & Therapy; 2000; Vol. 25 Issue 4
The article above contains foundational information. Articles below contain optional updates.

Personal Reflection Exercise #3
The preceding section contained information about treating HIV positive adolescents.  Write three case study examples regarding how you might use the content of this section in your practice.

QUESTION 9
What are two key questions adolescents with HIV have concerning disclosure? Record the letter of the correct answer the Answer Booklet

 
Others who bought this HIV/AIDS Course
also bought…

Scroll DownScroll UpCourse Listing Bottom Cap

Answer Booklet for this course | HIV/AIDS CEU Courses
Forward to Section 10
Back to Section 8
Table of Contents
Top

The article above contains foundational information. Articles below contain optional updates.
Interaction between antiretroviral boosters and corticosteroids can lead to development of Cushing's syndrome
An interaction between antiretroviral boosting agents and corticosteroids can lead to Cushing’s syndrome, according to French research published in the Journal of Antimicrobial Chemotherapy. Almost all the cases of Cushing’s syndrome identified among people with HIV were due to drug interactions between the boosting agents ritonavir or cobicistat and a corticosteroid. Moreover, the interaction was more likely to be serious among people with HIV than in HIV-negative individuals. Cushing’s syndrome sometimes emerged after only two weeks of taking the interacting medications.
Guidelines fail to address needs of adolescents living with HIV transitioning to adult health care in low- and middle-income countries
Only five of 12 low- and middle-income countries had transition guidelines, according to a systemic review of adolescents living with HIV transitioning from paediatric to adult health care published in AIDS and Behavior. The authors believe this to be the first review to survey the literature on barriers and facilitators of transition for adolescents living with HIV in low- and middle-income countries and to compare these factors to countries’ current guidelines.
Same-day initiation of ART feasible and safe without CD4 counts, Thai study shows
Three models of same-day antiretroviral therapy (ART), tested in different hospitals in Thailand, are feasible and safe, researchers report. The models have been implemented in Thailand since 2017, following a World Health Organization recommendation that all individuals diagnosed as HIV positive should receive ART on the same day of diagnosis, if they are ready.
Ageing population of people living with HIV in sub-Saharan Africa associated with cardiovascular risk factors
An ageing population of people living with HIV on antiretroviral therapy in countries in sub-Saharan Africa is associated with a significant increase in the prevalence of diabetes and obesity, according to an analysis of 44 countries with data from 2000 to 2016, published in the Journal of the International AIDS Society.
San Francisco HIV cases fall to a new low
The annual number of new HIV diagnoses in San Francisco has dipped below 200, falling to its lowest level since the peak of the epidemic in the early 1990s, according to the city's HIV Epidemiology Annual Report for 2018. Total new diagnoses fell to 197, with decreases seen in most population groups. However, diagnoses among African-American and Latino men showed an increase after declining for several years.

OnlineCEUcredit.com Login


Forget your Password Reset it!